Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Denali Therapeutics ( (DNLI) ) has shared an announcement.
On April 3, 2026, Denali Therapeutics said Takeda Pharmaceutical will terminate their 2018 collaboration to co-develop and co-commercialize DNL593, an investigational progranulin replacement therapy for GRN-related frontotemporal dementia. The decision, described as strategic and not data-driven, will take effect 60 days after notice, at which point Denali regains full global rights and intellectual property and has no further financial obligations to Takeda.
Denali, which has led development of DNL593, plans to continue the program independently and report results from its ongoing Phase 1/2 study in FTD-GRN by the end of 2026. The trial has fully enrolled 40 patients, and earlier interim data from healthy volunteers showed dose-dependent increases in cerebrospinal fluid progranulin and no significant safety signals, reinforcing Denali’s positioning around its clinically validated TransportVehicle blood-brain barrier-crossing technology in a field with no approved disease-modifying FTD treatments.
The most recent analyst rating on (DNLI) stock is a Hold with a $19.50 price target. To see the full list of analyst forecasts on Denali Therapeutics stock, see the DNLI Stock Forecast page.
Spark’s Take on DNLI Stock
According to Spark, TipRanks’ AI Analyst, DNLI is a Neutral.
The score is held back primarily by weak financial performance (widening losses, cash burn, and recent $0 revenue) and bearish technical signals. These are partly offset by strong, positive corporate catalysts (FDA accelerated approval and $200M non-dilutive funding) and a low-leverage balance sheet.
To see Spark’s full report on DNLI stock, click here.
More about Denali Therapeutics
Denali Therapeutics Inc. is a biotechnology company focused on developing biotherapeutics that cross the blood-brain barrier using its proprietary TransportVehicle platform. The company is building a portfolio of candidates targeting neurodegenerative diseases, lysosomal storage disorders and other serious conditions with high unmet medical need.
Average Trading Volume: 1,810,469
Technical Sentiment Signal: Buy
Current Market Cap: $3.27B
Learn more about DNLI stock on TipRanks’ Stock Analysis page.